

1 **COVID-19 antibody detection and assay performance** 2 **using red cell agglutination**

3 Running title: SARS-CoV-2 red cell assay and convalescent plasma

4 Kshitij Srivastava¹, Kamille A West¹, Valeria De Giorgi¹, Michael R Holbrook², Nicolai V.
5 Bovin^{3,4}, Stephen M Henry⁴ and Willy A Flegel¹

6
7 From the ¹Department of Transfusion Medicine, NIH Clinical Center, National
8 Institutes of Health, Bethesda, MD, USA; ²National Institute of Allergy and Infectious
9 Diseases (NIAID) Integrated Research Facility, National Institutes of Health, Frederick, MD,
10 USA; ³Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia; ⁴Centre
11 for Kode Technology Innovation, School of Engineering, Computer and Mathematical
12 Sciences, Faculty of Design and Creative Technologies, Auckland University of Technology,
13 Auckland, New Zealand.

14
15 Address for correspondence: Willy Albert Flegel, MD, Laboratory Services Section,
16 Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health;
17 Bethesda MD 20892, USA, e-mail: waf@nih.gov, Phone: (301) 594-7401, FAX: (301) 496-
18 9990

19 **Conflict of interest disclosure:** SMH and NVB are employees and stockholders in
20 Kode Biotech, the patent owner of Kode biosurface engineering technology. MRH performed
21 this work as an employee of Laulima Government Solutions, LLC (Orlando, FL). All other
22 authors declared having no competing financial interest.

23 **Statement of Disclaimer:** The views expressed do not necessarily represent the view
24 of the National Institutes of Health, the US Food and Drug Administration, the Department of

25 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Health and Human Services, or the U.S. Federal Government.

26 **Authorship contribution:** KS performed the SARS-CoV-2 kodecyte assay and wrote
27 the manuscript; KAW provided the convalescent plasma samples and was in charge of the
28 blood donors and collection; VDG provided the Ortho Total and IgG chemiluminescent assay
29 results; MRH provided the virus neutralizing assay results; SMH and NVB designed the C19-
30 kodecyte assay; WAF designed and coordinated the study and edited the manuscript. All
31 authors discussed the study and reviewed the manuscript.

32

33 **Key words:** COVID-19, SARS-CoV-2, C19-kodecyte, column agglutination technique

34

35

36 **Article word count** = 2,470 excluding abstract, title, references

37

38

39

40 **Abstract**

41 Red cells can be labelled with peptides from the SARS-CoV-2 spike protein and used
42 for serologic screening of SARS-CoV-2 antibodies. We evaluated 140 convalescent COVID-
43 19 patients and 275 healthy controls using this C19-kodecyte assay. The analytical
44 performance of the new assay was compared with a virus neutralizing assay and 2
45 commercial chemiluminescent antibody tests (Total assay and IgG assay, Ortho). The C19-
46 kodecyte assay detected SARS-CoV-2 antibodies with a sensitivity of 92.8% and specificity
47 of 96.3%, well within the minimum performance range required by FDA for EUA
48 authorization of serologic tests. The Cohen's kappa coefficient was 0.90 indicating an almost
49 perfect agreement with the Total assay. The Pearson correlation coefficient was 0.20 with the
50 neutralizing assay (0.49 with IgG, and 0.41 with Total assays). The limited correlation in
51 assay reaction strengths suggested that the assays may detect different antibody specificities.
52 Our easily scalable C19-kodecyte assay may vastly improve test capacity in blood typing
53 laboratories using their routine setups for column agglutination technique.

54

55 **Abstract word count** = 161 words

56

57

58

59 **Background**

60 The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel
61 betacoronavirus SARS-CoV-2, has resulted in global public health crisis. As of May 27 2021,
62 there have been more than 168 million confirmed cases of COVID-19, including more than 3
63 million deaths reported globally [1]. Vaccines against SARS-CoV-2 were first approved in
64 China on June 25, 2020 for limited use in the military [2], followed by Russia on August 11,
65 2020 for emergency use [3]. In the United States, the United States Food and Drug
66 Administration (FDA) issued the first emergency use authorization (EUA) for Pfizer-
67 BioNTech COVID-19 vaccine on December 11, 2020 [4]. Worldwide, 15 COVID-19
68 vaccines have been authorized or approved, as of May 24, 2021 [5].

69 On August 23, 2020, the FDA issued an EUA for COVID-19 convalescent plasma
70 (CCP) for the treatment of hospitalized COVID-19 patients [6]. CCP provides passive
71 immunity through neutralizing antibodies against SARS-CoV-2 virus, helps control infection
72 and modulates inflammatory response [7]. Only high-titer CCP to hospitalized older COVID-
73 19 patients early in the disease course has been shown to reduce the progression of disease [6,
74 8]. However, recent studies have concluded no clear benefit to the CCP therapy [9] with
75 many blood centers suspending collection of convalescent plasma.

76 Serologic assays detecting antibodies against the SARS-CoV-2 spike or nucleocapsid
77 proteins have been developed to advance our understanding of the prognosis and clinical
78 course of the disease, contribute to epidemiological research and aid in vaccine development.
79 These serologic assays are also used to identify asymptomatic individuals, evaluate immune
80 response in patients, identify of high-titer CCP units, determine duration and magnitude of
81 immunity conferred by SARS-CoV-2 vaccine, and assist in the prediction of disease
82 progression and epidemiology [10, 11]. The FDA has approved 79 SARS-CoV-2 antibody

83 assays under EUA [12]. Only 11 of these serologic assays were accepted in the manufacture
84 of high-titer COVID-19 convalescent plasma [6].

85 We recently developed a red cell agglutination-based assay to detect SARS-CoV-2
86 antibodies [13]. The assay uses peptide fragments of the SARS-CoV-2 spike protein to label
87 red cells (C19-kodecytes). These C19-kodecytes are agglutinated in the presence of SARS-
88 CoV-2 antibodies using routine serologic platforms. We perform a clinical evaluation of this
89 C19-kodecyte assay in CCP donors previously assessed with 2 commercial immunoassays
90 and a virus neutralizing assay [14].

91

92

93 **Materials and Methods**

94 **Study population.** COVID-19 convalescent plasma or EDTA anticoagulated whole
95 blood was prospectively collected between April 2020 and January 2021 from 140 donors (2
96 asymptomatic and 138 with mild to severe disease) [14], who had previously tested positive
97 for SARS-CoV-2 infection by real-time reverse transcription polymerase chain reaction
98 (rRT-PCR). Plasma samples were collected from 125 consecutive Ortho Total negative
99 healthy volunteer donors. An additional 150 plasma samples, collected in 2008, more than a
100 decade before the COVID-19 outbreak, were also included as negative controls to evaluate
101 specificity of the C19-kodeocyte assay. An individual vaccinated with Moderna COVID-19
102 vaccine was prospectively analyzed for antibody response using the C19-kodeocyte assay.
103 Plasma, erythrocytes, and buffy coat aliquots were separated and stored at -80 °C (plasma) or
104 in the vapor phase of liquid nitrogen containers (-150 °C; erythrocytes and buffy coat).

105 Institutional Review Board (IRB) approved protocols were NCT04360278,
106 NCT00001846 and NCT00067054, respectively, which entailed written informed consent.
107 The plasma controls from 2008 were collected under the Vaccine Research Center's (VRC),
108 National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health
109 sample collection protocol VRC 200 (NCT00067054) in compliance with the NIH IRB
110 approved procedures. All subjects met protocol eligibility criteria and agreed to participate in
111 the study by signing the NIH IRB approved informed consent. Research studies with these
112 samples were conducted by protecting the rights and privacy of the study participants.

113 **Anti-SARS-CoV-2 assays.** Two chemiluminescent immunoassays directed against
114 the SARS-CoV-2 spike glycoprotein, Ortho IgG (80.8% overall sensitivity and 98.1% overall
115 specificity) [15], and Ortho Total (IgG, IgA and IgM; 87.7% overall sensitivity and 95.2%
116 overall specificity) [15] (Ortho Clinical Diagnostics, Raritan, NJ, USA), authorized by FDA
117 under an EUA for use by laboratories certified under Clinical Laboratory Improvement

118 Amendments of 1988 (CLIA), were used to detect total binding antibodies against the SARS-
119 CoV-2 virus in all 140 CCP donors [14, 15]. The 125 healthy volunteer donors were only
120 tested with the Ortho Total assay. The 150 pre-COVID-19 plasma samples were presumed
121 negative for SARS-CoV-2 and not tested with either of the immunoassays.

122 **SARS-CoV-2 virus neutralizing assay.** The surface-exposed location of the spike
123 glycoprotein makes it a major target of neutralizing antibodies [16]. An in-house developed
124 fluorescence reduction neutralizing assay (FRNA; not authorized by FDA; sensitivity and
125 specificity data not available) [17] was performed to detect neutralizing antibodies against the
126 SARS-CoV-2 virus (NT50) in all 140 CCP samples [14].

127 **SARS-CoV-2 kodecytes.** Dual epitope bearing kodecytes were prepared using a
128 blend of FSL (Function-Spacer Lipid) constructs 1147 and 1255 (peptides fragments of the
129 SARS-CoV-2 spike protein) at concentrations 1.5 μ M and 2.5 μ M, respectively (C19-
130 kodecytes) [13]. FSL construct 808 (5 μ M), with weaker reaction strength as compared to
131 constructs 1147 and 1255 [13], was also tested in parallel. All samples reactive to C19-
132 kodecytes were also tested against control cells, either unmodified red cells or kodecytes
133 labelled with an unrelated FSL construct [13].

134 **Gel card column agglutination technique (CAT).** The RBC-antibody mixtures were
135 prepared directly in the gel card wells (ID Cards LISS/Coombs, no. 50531; Bio-Rad
136 Laboratories, Hercules, CA, USA) with 50 μ L of SARS-CoV-2 kodecytes at 1%
137 concentration and 25 μ L of antibody solution. Gel cards were incubated at 37 °C for 15 min
138 and centrifuged at 1,032 rpm for 10 minutes in an Ortho Workstation (Ortho Clinical
139 Diagnostics, Raritan, NJ) at room temperature. All reactions were read macroscopically. A
140 titer was determined as the highest dilution showing 1+* (weak positive) agglutination. The
141 grading of the agglutination reaction was scored as 12, 10, 8, 5, 3, 0 for titer 4+, 3+, 2+, 1+,
142 1+* and negative, respectively [13, 18]. A higher score can indicate the presence of a higher

143 antibody concentration. more antigens on the red cells, or a stronger antigen-antibody
144 affinity. Total score was calculated by adding the individual scores at two-fold serial
145 dilutions.

146 **Sensitivity and specificity.** The sensitivity of our assay was evaluated on consecutive
147 CCP samples collected from participants at various time points after rRT-PCR confirmation.
148 Assay sensitivity was calculated as the percentage of samples that tested positive with the
149 C19-kodecyte assay relative to the total number of PCR-confirmed COVID-19 positive
150 samples [Sensitivity = True Positive / (True Positive + False Negative)].

151 The specificity of our assay was calculated as the percentage of samples that tested
152 negative with the C19-kodecyte assay relative to the total number of COVID-19 negative
153 samples [Specificity = True Negative / (True Negative + False Positive)].

154 **Statistical analyses.** Unless stated otherwise, continuous data are given as median
155 (Quartile 1 – Quartile 3). Confidence intervals (95% CI) were calculated according to the
156 efficient-score method (corrected for continuity) [19]. Cohen’s kappa was used to evaluate
157 between methods agreements [20, 21]. Receiver operating characteristic (ROC) curves were
158 used to evaluate overall performance of the 2 Ortho and the C19-kodecyte assays.

159

160

161 **Results**

162 A total of 140 CCP samples and 275 healthy controls were analysed in the C19-
163 kodecyte assay (Supplementary Table S1). The median time interval from the onset of
164 symptoms and plasma donation was 78 days (Quartile 1 – Quartile 3, 53 – 111 days; range,
165 33 – 331 days). We compared our results with those of Ortho chemiluminescent
166 immunoassays and with a virus neutralizing assay.

167 **Ortho SARS-CoV-2 assays.** Ortho IgG assay was positive in 92.1% of CCP samples
168 (129/140) and Ortho Total assay was positive in 97.8% of CCP samples (137/140). The
169 median log anti-SARS-CoV-2 Signal/Cut-off (S/CO) ratio and inter-quartile range for each
170 assay were as follows: Ortho IgG (1.03, 0.73 – 1.22) and Ortho Total (2.46, 2.04 – 2.74) (Fig.
171 1).

172 **SARS-CoV-2 virus neutralizing assay.** Of the 140 CCP samples tested, neutralizing
173 data was not available for 40 (28.57%) samples. For the remaining 100 samples, there was a
174 broad range of neutralization against live SARS-CoV-2, with 2 (1.43%) samples
175 demonstrating high NT50 values of more than 600, and 5 (3.57%) samples with undetectable
176 NT50 values of less than 40 (Supplementary Fig. S1).

177 **C19-kodecyte assay.** Of the 140 CCP samples tested, C19-kodecyte assay was
178 negative in 10 (7.1%) samples (Supplementary Table S3). The median log anti-SARS-CoV-2
179 score and inter-quartile range for C19-kodecyte assay were 1.41, 1.20 – 1.60, respectively.
180 ROC curves were generated based on positive (140 SARS-CoV-2 rRT-PCR-positive) and
181 negative results (125 Ortho Total negative and 150 pre-COVID-19 samples). The results
182 showed that the area under the ROC curve (AUC) of C19-kodecyte reached 0.95 (95% CI:
183 0.93 - 0.97) with sensitivity and specificity values of 92.8% (95% CI: 86.9% - 96.3%) and
184 96.3% (95% CI: 93.2% - 98.1%), respectively (Supplementary Fig. S2).

185 C19-kodeocyte assay was used to test the antibody response in a vaccinated individual.
186 The Ortho Total assay gave positive results 14 days after the 1st vaccination and decreased 91
187 days later (data not shown). Using the C19-kodeocyte assay, the individual's plasma sample
188 tested positive 28 days after the 1st vaccination and increased a week later (score 40). The
189 antibody concentration decreased when tested 91 days later (data not shown).

190 **Assay comparison.** Almost all the CCP donors with longitudinal follow-up data (n =
191 40) showed a decrease in the antibody concentration from day 1 to their most recent
192 donation, which varies from 7 to 44 weeks (Fig. 2). We compared the neutralizing activity in
193 the CCP samples to C19-kodeocyte score as well as 2 clinical diagnostic assays (Ortho Total
194 and Ortho IgG). There was a universally positive relationship between NT50 and all 3
195 binding assays tested, with Spearman's correlation r ranging from 0.20 to 0.49 and linear R^2
196 values of 0.0796 to 0.2959 reflecting a weak linear relationship (Fig. 3). The strongest
197 positive correlation between assays was the Ortho Total and Ortho IgG assays (Spearman's r
198 = 0.87, $p = <0.001$).

199 A few CCP samples were identified with discordant Ortho (Total and IgG) and
200 neutralizing antibody S/CO ratios, including some with high neutralizing antibody and low
201 Ortho antibody S/CO ratio in individual assays and vice versa (Supplementary Table S3).
202 With positive and negative data available only for the C19-kodeocyte and Ortho Total assays,
203 the agreement between the 2 assays was considered as almost perfect [21], because the
204 Cohen's kappa was 0.90 (95% CI: 0.85-0.95) [20] (Supplementary Table S2).

205 There were 14 CCP donors that tested negative with at least one of the assays
206 (Supplementary Table S3). We observed 3 CCP donors with no detectible antibody in the
207 C19- kodeocyte and both Ortho assays, without virus neutralizing assay data available.
208 Additionally, C19-kodeocyte assay was repeatedly positive in 10 healthy donors (6 Ortho
209 Total negative and 4 pre-COVID-19).

210

211 **Discussion**

212

213 The SARS-CoV-2 kodecye based antibody diagnostic assay is a simple test for rapid

214 screening of SARS-CoV-2 antibodies in human plasma [13]. The assay can be easily

215 established in a blood bank, using its typical equipment, and is well suited for surveillance

216 studies. We compared the C19-kodecye assay with 2 established commercial assays (Ortho

217 Total and Ortho IgG) and an in-house developed virus neutralization assay. All 4 assays

218 detect antibodies directed against the SARS-CoV-2 spike glycoprotein [13, 15, 16].

219 In our study, the C19-kodecye assay results demonstrated excellent analytical

220 performance and exhibited almost perfect agreement with the Ortho Total assay (Cohen's

221 kappa = 0.90), albeit with limited correlation (0.41). However, a small proportion (14/140

222 CCP donors and 10/275 controls) of samples differed (Supplementary Table S3). This pattern

223 may represent varied assay sensitivity, specificity, or a combination of both among the

224 different assays as the C19-kodecye assay primarily detects IgG antibody while the Ortho

225 Total assay detects IgG, IgM and IgA antibodies. This may also suggest that COVID-19

226 patients develop a broad antibody repertoire against multiple SARS-CoV-2 proteins and

227 epitopes and different assays detect diverse antibody specificities.

228 Another possible explanation for the weak correlation, despite excellent agreement,

229 can be the difference in the underlying principle of the assays. The antigens (peptides) on the

230 kodecytes are small, monospecific epitopes that react with a single antigen binding (Fab)

231 region of antibody. Therefore, in contrast to recombinant protein diagnostic assays where

232 multiple epitopes are present and are available to interact with different antibodies, C19-

233 kodecytes with 2 epitopes (1147 and 1255), will probably only react with 2 very specific

234 antibodies of the polyclonal antibody pool. Furthermore, it is speculated that kodecye

235 peptide epitopes are located in the glycocalyx of the red cell membrane and are surrounded

236 by carbohydrates and proteins [13, 22], which may act like a natural buffer against low-

237 affinity IgG antibodies and the lower affinity IgM antibodies and allows for the use of
238 undiluted plasma samples.

239 A decrease in the SARS-CoV-2 antibody concentrations was shown for all CCP
240 donors including the single vaccinated donor and has been reported previously in multiple
241 studies [14, 23-26]. Antibody concentrations are also known to decay faster in individuals
242 with mild infection or asymptomatic disease [27-29] resulting in no detectable SARS-CoV-2
243 antibodies in commercial antibody detection assays [30, 31].

244 The C19-kodecyte assay sensitivity (92.1%) was much greater than that published for
245 the 2 Ortho assays (IgG: 80.8% and Total: 87.7%) [15]. The C19-kodecyte assay also
246 demonstrated a high specificity (95.2%) and did not differ significantly from the Ortho assays
247 (IgG: 98.1% and Total: 95.2%). The sensitivity and specificity values of the C19-kodecyte
248 assay are well within the minimum performance range of FDA issued EUA authorized
249 serology tests (90% sensitivity and 95% specificity) [32].

250 The C19-kodecyte assay, although a beta version with a possibility of further
251 refinement, is comparable to other FDA authorized or approved assays. However, an
252 optimization can still be attempted and improvements seem achievable for sensitivity and
253 specificity by adjusting the sequence of peptides and the FSL construct concentrations.
254 Slightly changing the existing peptide sequences by shifting or elongating them either left or
255 right into the flanking sequences has the potential to improve both sensitivity and specificity
256 [33]. Alternatively, different peptides could be evaluated and when testing CCP samples with
257 a different SARS-CoV-2 spike protein sequence (Peptide 808), 3 samples that tested false
258 negative in the C19-kodecyte assay tested positive with Peptide 808-kodecyte assay
259 (Supplementary Table S3). Likewise, optimization of the concentration of peptides during
260 kodecyte preparation can also improve reaction specificity of the assay.

261 The unusually flexibility of the C19-kodeocyte assay can easily be adapted using
262 different peptides from the SARS-CoV-2 spike and nucleocapsid proteins. This approach
263 allows to modify the assay specificity to determine the duration and magnitude of immunity
264 conferred by SARS-CoV-2 vaccine which would be an advantage for population surveillance
265 for ongoing infection and maintenance of immunity.

266 In summary, we performed an analytical validation of the C19-kodeocyte SARS-CoV-
267 2 immunoassay in 140 clinical samples. Our easily scalable C19-kodeocyte assay can be
268 operated in blood typing laboratories worldwide using routine setups for column
269 agglutination or tube techniques [13] to evaluate patients and convalescent donors. The
270 technique could vastly improve assay capacity, particularly in countries with under-
271 developed health systems.

272

273

274 **Acknowledgments.** The authors thank Marina U Bueno for sample coordination and
275 Sita Shrestha and Nadine R Dowling for technical support in the serologic testing. We
276 acknowledge the contributions of our colleagues Martin R Gaudinski, Julie E Ledgerwood,
277 Maria B Florez, Emily E Coates and Ingelise J Gordon at the Vaccine Research Center
278 (VRC) Clinical Trials Program, NIAID and Robin A Gross, Janie Y Liang, Steven D Mazur
279 and Elena N Postnikova at the Integrated Research Facility (IRF), Frederick, NIAID. This
280 work was supported in whole or in part by the Intramural Research Program (project ID ZIC
281 CL002128) of the NIH Clinical Center at the National Institutes of Health; National Institute
282 of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health
283 and Human Services (DHHS), under Contract No. HHSN272201800013C; and by the New
284 Zealand Ministry of Business, Innovation & Employment COVID-19 Innovation
285 Acceleration Fund, contract CIAF 0490.

286

287 **Supporting Information**

288 Additional Supporting Information may be found in the online version of this article:

289 **Supplementary Fig. S1.** Neutralizing titer (NT50) values in the 140 CCP samples.

290 **Supplementary Fig. S2.** ROC curve of C19-kodecyte assay.

291 **Supplementary Table S1.** Characteristics of COVID-19 convalescent plasma donors.

292 **Supplementary Table S2.** Agreement and Cohen's kappa between C19-kodecyte and Ortho
293 Total assays.

294 **Supplementary Table S3.** CCP donors with inconsistent results in the 5 assays.

295

296 **Web Resources**

297 <http://vassarstats.net/clin1.html#note>

298 <https://www.graphpad.com/quickcalcs/kappa2/>

299

300

301 **Legend to the Figure**

302

303 **Fig. 1. Anti-SARS-CoV-2 plasma S/CO ratios as measured using the Ortho Total**
304 **and Ortho IgG assays.** Shown are the antibody S/CO ratios against SARS-CoV-2 spike (S)
305 protein in the convalescent plasma using the 2 Ortho assays. The horizontal bars indicate
306 medians, and the shaded gray areas interquartile ranges. Each circle represents one patient.

307

308 **Fig. 2. Correlation plots comparing all assays tested, with linear curve fitting R^2**
309 **value shown.** Spearman's correlation (r) for pairwise comparisons of each assay tested is
310 also shown. Each circle represents one patient. Total score was calculated by adding the
311 individual scores at two-fold serial dilutions.

312

313 **Fig. 3. Change in Strength (score), Ortho Total and Ortho IgG S/CO ratio over**
314 **time for each individual donor.** Each data point represents the antibody levels calculated
315 from an individual convalescent plasma donation, and each color represents an individual
316 donor followed longitudinally. Each timepoint was calculated using the day of donation and
317 the donor's self-reported first day of symptoms. Total score was calculated by adding the
318 individual scores at two-fold serial dilutions.

319

320


321 **References**

- 322 1. WHO coronavirus disease (COVID-19) dashboard. Geneva: World Health Organization,
323 2020 (<https://covid19.who.int/>; accessed 5/27/2021).
- 324 2. Reuters. CanSino's COVID-19 vaccine candidate approved for military use in China
325 ([https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-](https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ)
326 [vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ](https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ); accessed
327 5/27/2021).
- 328 3. Ullah Z, Rahim Z. Putin says Russia has approved 'world first' Covid-19 vaccine. But
329 questions over its safety remain ([https://www.cnn.com/2020/08/11/europe/russia-](https://www.cnn.com/2020/08/11/europe/russia-coronavirus-vaccine-putin-intl/index.html)
330 [coronavirus-vaccine-putin-intl/index.html](https://www.cnn.com/2020/08/11/europe/russia-coronavirus-vaccine-putin-intl/index.html); accessed 5/27/2021).
- 331 4. FDA. Pfizer-BioNTech COVID-19 vaccine ([https://www.fda.gov/emergency-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
332 [preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
333 [vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine); accessed 5/27/2021).
- 334 5. Craven J. COVID-19 vaccine tracker ([https://www.raps.org/news-and-articles/news-](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker)
335 [articles/2020/3/covid-19-vaccine-tracker](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker); accessed 5/27/2021).
- 336 6. Denise M. Hinton, U.S. Food & Drug Admin., U.S. Dep't of Health & Human Servs.,
337 Emergency Use Authorization for COVID-19 Convalescent Plasma (originally issued Aug.
338 23, 2020, and subsequently reissued with revisions) available at
339 <https://www.fda.gov/media/141477/download>.
- 340 7. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible
341 mechanisms of action. *Autoimmun Rev* **2020**; 19:102554.
- 342 8. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent
343 severe covid-19 in older adults. *N Engl J Med* **2021**; 384:610-8.

- 344 9. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with
345 clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. *Jama*
346 **2021**; 325:1185-95.
- 347 10. Marks P. FDA In Brief: FDA updates Emergency Use Authorization for COVID-19
348 convalescent plasma to reflect new data ([https://www.fda.gov/news-events/fda-brief/fda-
349 brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-
350 data](https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-349 data); accessed 5/27/2021).
- 351 11. West R, Kobokovich A, Connell N, Gronvall GK. COVID-19 antibody tests: a valuable
352 public health tool with limited relevance to individuals. *Trends Microbiol* **2021**; 29:214-23.
- 353 12. FDA. Individual EUAs for serology tests for SARS-CoV-2
354 ([https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-
355 authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-
356 immune-response-tests-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-355 authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-356 immune-response-tests-sars-cov-2); accessed 5/27/2021).
- 357 13. Nagappan R, Flegel WA, Srivastava K, et al. COVID-19 antibody screening with SARS-
358 CoV-2 red cell kodeocytes using routine serologic diagnostic platforms. *Transfusion* **2021**;
359 61:1171-80.
- 360 14. De Giorgi V, West KA, Henning AN, et al. Anti-SARS-CoV-2 serology persistence over
361 time in COVID-19 convalescent plasma donors. *medRxiv* **2021**:2021.03.08.21253093.
- 362 15. Padoan A, Bonfante F, Pagliari M, et al. Analytical and clinical performances of five
363 immunoassays for the detection of SARS-CoV-2 antibodies in comparison with
364 neutralization activity. *EBioMedicine* **2020**; 62:103101.
- 365 16. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function,
366 and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **2020**; 181:281-92.e6.

- 367 17. Bennett RS, Postnikova EN, Liang J, et al. Scalable, micro-neutralization assay for
368 qualitative assessment of SARS-CoV-2 (COVID-19) virus-neutralizing antibodies in human
369 clinical samples. *Viruses* **2021**; 13:893.
- 370 18. Marsh WL. Scoring of hemagglutination reactions. *Transfusion* **1972**; 12:352-3.
- 371 19. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of
372 seven methods. *Stat Med* **1998**; 17:857-72.
- 373 20. Cohen J. A coefficient of agreement for nominal scales. *Educ Psychol Meas* **1960**; 20:37-
374 46.
- 375 21. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
376 *Biometrics* **1977**; 33:159-74.
- 377 22. Ryzhov IM, Tuzikov AB, Nizovtsev AV. SARS-CoV-2 peptide bioconjugates designed
378 for antibody diagnostics (in press). *Bioconjugate Chemistry* **2021**.
- 379 23. Prus K, Alquist CR, Cancelas JA, Oh D. Decrease in serum antibodies to SARS-CoV-2 in
380 convalescent plasma donors over time. *Transfusion* **2021**; 61:651-4.
- 381 24. Yamayoshi S, Yasuhara A, Ito M, et al. Antibody titers against SARS-CoV-2 decline, but
382 do not disappear for several months. *EClinicalMedicine* **2021**; 32:100734.
- 383 25. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2
384 infection persist for months. *Science* **2020**; 370:1227-30.
- 385 26. Perreault J, Tremblay T, Fournier MJ, et al. Waning of SARS-CoV-2 RBD antibodies in
386 longitudinal convalescent plasma samples within 4 months after symptom onset. *Blood* **2020**;
387 136:2588-91.
- 388 27. Ibarondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2
389 antibodies in persons with mild Covid-19. *N Engl J Med* **2020**; 383:1085-7.
- 390 28. van der Heide V. Neutralizing antibody response in mild COVID-19. *Nat Rev Immunol*
391 **2020**; 20:352.

- 392 29. Payne DC, Smith-Jeffcoat SE, Nowak G, et al. SARS-CoV-2 infections and serologic
393 responses from a sample of U.S. navy service members - USS Theodore Roosevelt, April
394 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69:714-21.
- 395 30. Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited
396 evidence, many remaining questions. *Jama* **2020**; 323:2245-6.
- 397 31. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a
398 COVID-19 recovered patient cohort and their implications. *medRxiv*
399 **2020**:2020.03.30.20047365.
- 400 32. FDA. Template for test developers of serology tests that detect or correlate to neutralizing
401 antibodies (<https://www.fda.gov/media/146746/download>; accessed 5/27/2021).
- 402 33. Heathcote D, Carroll T, Wang JJ, et al. Novel antibody screening cells, MUT+Mur
403 kodeocytes, created by attaching peptides onto red blood cells. *Transfusion* **2010**; 50:635-41.
- 404
- 405



406

407

408




409

410

411


Figure 1

412
413
414



415
416
417
418
419
420
421
422

Figure 2



423

424

Figure 3